Skip to main content
Trillium Therapeutics Inc. logo

Trillium Therapeutics Inc. — Investor Relations & Filings

Ticker · TRIL ISIN · CA89620X5064 TSX Professional, scientific and technical activities
Open in API
Filings indexed 397 across all filing types
Latest filing 2020-03-10 Regulatory Filings
Country CA Canada
Listing TSX TRIL

About Trillium Therapeutics Inc.

http://www.trilliumtherapeutics.com

Trillium Therapeutics Inc. was a clinical-stage biopharmaceutical company specializing in immuno-oncology. The company focused on the discovery and development of innovative therapies for the treatment of cancer, particularly those targeting the immune system and its regulation. Trillium maintained preclinical programs and advanced several candidates through clinical trials in the oncology therapy area. In November 2021, Trillium Therapeutics was acquired by Pfizer Inc. and now operates as an integrated entity within Pfizer's global biopharmaceutical research and development structure, continuing its focus on advancing cancer treatments.

Recent filings

Filing Released Lang Actions
Annual MD&A - English.pdf
Regulatory Filings
2020-03-10 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a short announcement responding to market activity, specifically addressing a regulatory request from IIROC about unusual trading volume and price movement. It does not contain financial statements, detailed financial data, or any report content. It is a regulatory announcement clarifying the company's position on market rumors or activity. The document length is only 1187 characters, indicating it is a brief statement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-02-28 English
News release - English.pdf
Board/Management Information Classification · 95% confidence The document is a press release announcing changes to the company's Board of Directors, including appointments and resignations. It does not contain financial statements, audit information, or detailed management reports. It is not an earnings release, annual report, or any form of financial or regulatory filing. The content focuses solely on board membership changes, which fits the category of Board/Management Information (MANG). The document length is 5513 characters, sufficient for a detailed announcement but not a full report. Therefore, the appropriate classification is MANG with high confidence.
2020-02-07 English
Material change report - English.pdf
Regulatory Filings
2020-02-07 English
Material change report - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a Form 51-102F3 Material Change Report filed by Trillium Therapeutics Inc. It details a material change event, specifically the closing of a public offering of common shares and preferred shares, including the amount raised, use of proceeds, and related details. The document includes a press release about the offering and references regulatory filings on SEDAR and the SEC. The content focuses on a financing event and capital raising activity, not on financial results, management changes, or other report types. The document length is 7473 characters, which is sufficient to contain substantive information rather than just an announcement. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2020-02-07 English
Non-issuer's submission to jurisdiction and appointment of agent.pdf
Regulatory Filings Classification · 95% confidence The document is a submission form related to jurisdiction and appointment of an agent for service of process under National Instrument 41-101, which pertains to prospectus requirements. It includes details about the issuer, filing person, and agent for service of process, but does not contain financial statements, management discussion, or any report content. The document length is 3919 characters, which is relatively short and more consistent with a regulatory or legal filing rather than a full report. It is not an announcement of a report but a formal regulatory submission related to securities distribution. Therefore, it fits best under Regulatory Filings (RNS) as it does not match any other specific report category and is a compliance-related filing.
2020-02-06 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.